Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback